RRML - Hypoxia-inducible factor HIF-1α: pharmacogenetic perspective for bevacizumab therapy individualization
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2016): 55%

Română English


SCImago Journal & Country Rank


Advanced search


Top 10 downloaded articles
- January 2020 -
 
Hemolysis has no influence on ... 17
The role of neutrophil to lymp... 12
Acute effects of recreational ... 11
The usefulness of neutrophil/l... 11
Is there a correlation between... 10
The direct deleterious effect ... 10
The evaluation of the reverse ... 9
The angiotensinogen gene polym... 8
Undetectable hemoglobin in a p... 8
Relationships between serum pr... 8

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 16(3)/2009
XML
TXT

Hypoxia-inducible factor HIF-1α: pharmacogenetic perspective for bevacizumab therapy individualization

Roxana-Georgiana Tauser, Eloae Florin Zugun, Daniela Jitaru, Eugen Carasevici


Abstract:

Pharmacogenetics of innovative angiogenic-targeted monoclonal antibody therapy, yet in its infancy, will be crucial in treatment individualization according to the genetic profile of each patient and molecular features of tumors. Bevacizumab (Avastin) specifically targets the key promotor of angiogenesis - vascular endothelial growth factor (VEGF), whose transcription is critically regulated by hypoxia-inducible factor HIF-1α. The present paper points out the clinical relevance of HIF-1α common genetic polymorphisms to the inter-individual variability in response to anti-VEGF-targeted monoclonal antibody therapeutic regimens, with special reference to colorectal cancer.

Keywords: pharmacogenetics,bevacizumab,hypoxia inducible factor,cancer

 
  PDF Download full text PDF
(253 KB)
     
 
How to cite
Tauser RG, Zugun EF, Jitaru D, Carasevici E. Hypoxia-inducible factor HIF-1α: pharmacogenetic perspective for bevacizumab therapy individualization. Rev Romana Med Lab. 2009;16(3):7-12